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Dr Joseph Friedberg (Philadelphia, Pa). The role of SLRs has
been the focus of intense scrutiny by thoracic surgeons for de-
cades, and the exact role has yet to be rigorously defined. We
are still forced to fall back on the LCSG analysis from 1995 as
the final word until the upcoming randomized trials from the Can-
cer and Leukemia Group B and the Japanese Clinical Oncology
Group are completed. Your study provides more compelling
evidence, however, that there is clearly a role for SLR in some
of our patients.
My first question relates to the study population. As I read
the article, I was struck at how astoundingly well matched
the 2 groups were in this study, right down to the percentage
with college educations. I believe this is a particular strength
of this study in that it allows for an accurate assessment of out-
comes attributable to the surgical procedure. A potential weak-
ness of this study, however, arises from this same degree of
uniformity. Specifically, this study is based on a subgroup of
a subgroup—a group of patients who qualified for and enrolled
in a lung cancer screening trial and then developed solid nod-
ules while in that trial. Do you offer any cautions or see
any reasons why your results would not apply to the more gen-
eral population of patients with lung cancer we see in our
practices?
Dr Altorki. I don’t believe this study is a practice-changing
study. However, it is a study that calls for more equipoise in
terms of our approach to the treatment of lung cancer using
limited resections. We have applied these operations in patients
who would be candidates for both lobectomy and SLR. Patients
who are poor candidates for lobectomy should be treated by
SLR.
Dr Friedberg. My second question centers on another un-
usual situation for the general population of patients with lung
cancer. All of these patients had their surgery performed by gen-
eral thoracic surgeons, not just general thoracic surgeons, but
highly qualified general thoracic surgeons. Within this context,
I was surprised that 70% of the SLRs were performed as
wedges, not anatomic segmentectomies. I was also surprised
that more than 40% of the patients undergoing SLR and approx-
imately one quarter of the patients undergoing lobectomy did
not have even 1 mediastinal lymph node biopsied. One
would expect, on the basis of the LCSG analysis and common
sense, that some of these patients, especially those undergoing
SLR, were understaged or undertreated, yet the results
are as good as anything in the literature. How do you reconcile
that?ery c February 2014
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SDr Altorki. Let me take the second part first. I do agree with
you that the assessment of the mediastinal nodes was disap-
pointing. However, it exceeds what is in the published literature.
We need to further educate about the therapeutic and prognostic
impact of mediastinal nodal staging, particularly in patients in
whom an SLR is performed.My guess is that most of these patients
underwent video-assisted thoracic surgery, and, as you know,
mediastinal nodal assessment by video-assisted thoracic surgery
may not be as straightforward as it is by the open procedure, so
that’s probably why they were skipped.
To go back to the wedge resection, many may have thought
going into this that a 1-cm or 1.2-cm tumor may be effectively
treated by wedge resection, and that is the job we have to address
in the ongoing randomized trials to try and clarify if there is indeed
a role for wedge resection.
Dr Friedberg. I am curious about the decision to omit patients
with ground-glass opacities from the study. I suspect many of us,
given the controversy surrounding SLR, are more likely to be
aggressive with using SLRs for a slowly progressing ground-glass
opacity than a solid nodule. Do you know how many patients were
excluded from the study because their nodules weren’t solid and
do you have any thoughts on the applicability of SLRs for these
patients?
Dr Altorki. We had this discussion, and I voted strongly to
exclude them. I do believe that they are a group of patients who
exhibit a different biological behavior than those with solid nod-
ules, and we wanted to focus on a specific group of patients. But
I agree with you that this is a group that needs to be studied and
we hope to report on.
Dr Friedberg. They are the ones who are more likely to
develop something down the road requiring additional surgery. It
seems to me they would be the best candidates for this.
Dr Altorki. I think they are good candidates for SLR, yes, but I
do think they have to be studied separately.
Dr Scott Swanson (Boston, Mass). I like this study, Nasser. I
was struck by the 5% of second tumors in the lobectomy specimen.
Presumably it is the same in the wedge, but the local recurrence
rates weren’t different. Do you have any data about little nodules
that were being followed in that wedge group and what happened
or why that is?
Dr Altorki. That number is consistent with the published liter-
ature from Japan specifically and from our institution outside of
the I-ELCAP. These are usually not detected clinically on the
CT scans. We do have some patients in the Cancer and Leukemia
Group B trial in whom a wedge resection was performed, and even
in thewedge, there are additional nodules. The bottom line is that it
did not affect lung cancer–specific survival. But I’m concerned
about them, as you are.
Dr L. Penfield Faber (Chicago, Ill). Dr Altorki, I compliment
you on an excellent presentation. I would also like to thank my
good friends, Drs Thurer, Kohman, and Harvey Pass, for substan-
tiating the surgical concept of surgical resection for primary lung
cancer that Dr Jensik and I reported on 34 years ago, both qualified
general thoracic surgeons. We described 168 patients with a 53%
5-year survival. We resected larger tumors, greater than 3 cm, and
our lymph node staging was inadequate, and I think that accounts
for our low survival compared with what we see today. With theThe Journal of Thoracic and Caguidelines reported today, I believe segmental resection for pri-
mary lung cancer is a good operation.
Dr Altorki. I have to acknowledge the pioneering contribution
of Dr Faber and, as a displaced Chicagoan, of Dr Jensik as well. So
I thank you for your efforts.
Dr Jose Rodriguez (Dayton, Ohio). I noticed that in your 51 or
52 SLRs, there were maybe 18 that were segmentectomies. It was
not exactly described whether theywere anatomic or nonanatomic.
Do you think that it is a low number of segmentectomies to
compare with approximately 200 lobectomies? Do you think
that it is a low-power study to say that a segmentectomy might
be better?
I noticed that 4% to 6% of your SLRs were upstaged to stage
II or III because of N1 or N2 unexpected disease. What did you
do with those patients? Now you need to give adjuvant treatment,
and, in my opinion, they received maybe a suboptimal resection
for a stage II or III. I would be concerned that we are advising
surgeons to do an SLR when we are going to have maybe 5%
to 7% or 10% of patients who will have a suboptimal resection
due to unexpected stage II and III. I would like you to comment
on that.
Dr Altorki.We are not advising the surgeon to do anything.We
are just advising the surgeon to develop some equipoise. We
advise the surgeon that the data from the LCSG are no longer rele-
vant and that you should approach this whole matter with a new
frame of mind. We need to do a study that compares one with
the other.
Dr Daniel Miller (Atlanta, Ga). Did you go back and look at all
and see if there was a difference in the pathologic upstaging in re-
gard to a nodule that was found on the incident scan versus the
prevalent scan? Many times when we have found these original
nodules, they are a bit more biologically active, they might already
have nodal involvement and so forth. It would be an interesting
question. As we look at the follow-up scans, those might be better
survival and so forth and be something to look at because you have
a larger number of patients.
Dr Altorki. You are saying segregate the cancers on the base-
line from the cancers on the annual repeat?
Dr Miller. Exactly, yes.
Dr Altorki. That information has been published by I-ELCAP
before. Conceptually, though, we do think those that occur on the
annual repeat are more likely to be the more aggressive ones than
those detected on the baseline scans. I agree with you.
Dr Caio Sterse Da Mata (Sao Paulo, Brazil). What was the
criteria you used to perform a wedge versus a segmentectomy?
Dr Altorki. These patients were involved in the local screening
program, and the management was left to the local tumor commit-
tees of the local hospitals. We did not mandate any type of resec-
tion or how the resection should be done.
Dr Da Mata. There was no inclusion or exclusion criteria for
this?
Dr Altorki. No. The local surgeon, who was usually a board-
certified or equivalent certified thoracic surgeon, made the deci-
sion about that.
Dr Frank Detterbeck (New Haven, Conn). Dan Miller is al-
ways a step ahead of me and asked more or less the question I
wanted to ask.rdiovascular Surgery c Volume 147, Number 2 763
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SI have 2 follow-up points. You can look at your data to find out
how many of these were baseline versus follow-up scans and do
that analysis, and I would stimulate you to perhaps ask the ques-
tion: In your practice, because you are in an area where there is
a fair amount of screening performed, but there is also a fair
amount of incidental scanning going on, can you look at whether
incidental scanning gives us similar results to screening? That
would have a lot of impact in the generalizability of the results
that you have just reported.
Dr Altorki. The crux of the question is that these were patients
in a screening trial, and therefore they were a special cohort. I
accept that, and we don’t say that in our summary statement.764 The Journal of Thoracic and Cardiovascular SurgDoes that translate into what you find in somebody who comes
to your office with a CT scan in hand? I think to answer that ques-
tion we have an ongoing randomized trial.
Dr Joseph Shrager (Stanford, Calif). I want to go back to the
issue of the tumor formerly known as bronchioloalveolar carci-
noma. You said solid nodules, but does that mean part-solid
nodules? You don’t have any nodules in there that are half
ground-glass or anything like that?
Dr Altorki. No. We excluded all part-solid and nonsolid nod-
ules from this analysis.
Dr Shrager. Okay. I think that’s a really important point.
Dr Altorki. I agree with you, yes.ery c February 2014
